– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection MELBOURNE, Australia and MILAN, Italy, Sept. 11, 2023 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of complications associated with respiratory viral infections.

–INNA-051与安慰剂相比增加了多种抗病毒效应基因的早期表达，并缩短了确诊流感感染参与者的病毒脱落时间-墨尔本，澳大利亚和米兰，意大利，2023年9月11日（GLOBE NEWSWIRE）-ENA Respiratory，一家临床阶段制药公司宣布INNA-051第二阶段流感挑战研究的积极数据，开发中的一流，广谱，先天免疫调节剂，用于预防与呼吸道病毒感染相关的并发症。

As previously reported, data from post-hoc analyses excluding those with pre-existing immunity against the challenge virus strain showed that INNA-051-treated participants with laboratory-confirmed infection had a statistically significant shorter duration of infection. New data reported today show that in this population, INNA-051 resulted in early stimulation of multiple genes that play important roles in the response to viral infections, including type I and III interferons.

如先前报道的，来自事后分析的数据（不包括具有针对攻击病毒株的预先存在的免疫力的那些）显示，具有实验室确认的感染的INNA-051治疗的参与者具有统计学显着更短的感染持续时间。今天报道的新数据显示，在这个人群中，INNA-051导致多种基因的早期刺激，这些基因在对病毒感染（包括I型和III型干扰素）的应答中起重要作用。

These results support the observed accelerated viral clearance. The biomarker data were presented in a late-breaking abstract oral session and the clinical data were discussed at a poster session at the European Respiratory Society meeting, which is taking place in Milan, Italy, September 9-13. “The data presented today support the clinical potential of INNA-051 in individuals at risk for more severe outcomes resulting from viral respiratory infections,” said Christophe Demaison PhD, Managing Director and CEO of ENA Respiratory.

这些结果支持观察到的加速病毒清除。生物标志物数据在晚些时候的抽象口头会议上提出，临床数据在9月9日至13日在意大利米兰举行的欧洲呼吸学会会议的海报会议上进行了讨论。ENA respiratory总经理兼首席执行官Christophe Demaison博士说：“今天提供的数据支持INNA-051在有病毒性呼吸道感染导致更严重后果风险的个体中的临床潜力。

“These data provide important insights into the molecular mechanisms that underlie the observed decrease in duration of infection in this flu challenge study. Together with our Phase 1 and preclinical data, the results provide a cle.

“这些数据为本次流感攻击研究中观察到的感染持续时间减少的分子机制提供了重要见解。与我们的第一阶段和临床前数据一起，结果提供了一个cle。